A series of heteroleptic, neutral iridium(III) complexes of the form [Ir(L) 2 (N^O)] (where L = cyclometalated 2,3-disubstituted quinoxaline and N^O = ancillary picolinate or pyrazinoate) are described in terms of their synthesis and spectroscopic properties, with supporting computational analyses providing additional insight into the electronic properties. The 10 [Ir(L) 2 (N^O)] complexes were characterized using a range of analytical techniques (including 1 H, 13 C, and 19 F NMR and IR spectroscopies and mass spectrometry). One of the examples was structurally characterized using X-ray diffraction. The redox properties were determined using cyclic voltammetry, and the electronic properties were investigated using UV−vis, time-resolved luminescence, and transient absorption spectroscopies. The complexes are phosphorescent in the red region of the visible spectrum (λ em = 633−680 nm), with lifetimes typically of hundreds of nanoseconds and quantum yields ca. 5% in aerated chloroform. A combination of spectroscopic and computational analyses suggests that the long-wavelength absorption and emission properties of these complexes are strongly characterized by a combination of spinforbidden metal-to-ligand charge-transfer and quinoxaline-centered transitions. The emission wavelength in these complexes can thus be controlled in two ways: first, substitution of the cyclometalating quinoxaline ligand can perturb both the highest occupied molecular orbital (HOMO) and lowest unoccupied molecular orbital levels (LUMO, Cl atoms on the ligand induce the largest bathochromic shift), and second, the choice of the ancillary ligand can influence the HOMO energy (pyrazinoate stabilizes the HOMO, inducing hypsochromic shifts).

Six substituted ligands based upon 2‐(naphthalen‐1‐yl)quinoline‐4‐carboxylate and 2‐(naphthalen‐2‐yl)quinoline‐4‐carboxylate have been synthesised in two steps from a range of commercially available isatin derivatives. These species are shown to be effective cyclometallating ligands for IrIII, yielding complexes of the form [Ir(C^N)2(bipy)]PF6 (where C^N=cyclometallating ligand; bipy=2,2′‐bipyridine). X‐ray crystallographic studies on three examples demonstrate that the complexes adopt a distorted octahedral geometry wherein a cis‐C,C and trans‐N,N coordination mode is observed. Intraligand torsional distortions are evident in all cases. The IrIII complexes display photoluminescence in the red part of the visible region (668–693 nm), which is modestly tuneable through the ligand structure. The triplet lifetimes of the complexes are clearly influenced by the precise structure of the ligand in each case. Supporting computational (DFT) studies suggest that the differences in observed triplet lifetime are likely due to differing admixtures of ligand‐centred versus MLCT character instilled by the facets of the ligand structure. Triplet–triplet annihilation upconversion (TTA‐UC) measurements demonstrate that the complexes based upon the 1‐naphthyl derived ligands are viable photosensitisers with upconversion quantum efficiencies of 1.6–6.7 %.

A series of ligands have been synthesized based upon a polysubstituted 2-phenylquinoxaline core structure. These ligands introduce different combinations of fluorine and methyl substituents on both the phenyl and quinoxaline constituent rings. The resultant investigation of these species as cyclometalating agents for Ir(III) gave cationic complexes of the form [Ir(C^N) 2 (bipy)]PF 6 (where C^N = cyclometalating ligand; bipy = 2,2′-bipyridine). X-ray crystallographic studies were conducted on four complexes and each revealed the expected distorted octahedral geometry based upon a cis-C,C and trans-N,N ligand arrangement at Ir(III). Supporting computational studies predict that each of the complexes share the same general descriptions for the frontier orbitals. TD-DFT calculations suggest MLCT contributions to the lowest energy absorption and a likely MLCT/ILCT/LLCT nature to the emitting state. Experimentally, the complexes display tunable luminescence across the yellow-orange-red part of the visible spectrum (λ em = 579−655 nm).

A novel duloxetine ion-selective poly(vinyl chloride) membrane electrode based on the ion-pair complex of duloxetine with phosphomolybdic acid was prepared with diocyl phthalate as a plasticizer. The electrode exhibits a linear response with a slope of 56.9 mV decade :1 of duloxetine concentration at 25 AE 0.1 C for the optimum electrode prepared with a membrane consisting of 10.0% ion pairs. The electrode response was not sensitive to pH changes from 4.30-8.35 and was not affected by possible interfering species such as common inorganic cations, sugars and amino acids. It has a relatively fast response time less than (15 s) and the lifetime was about 2 months during which it could be used without any measurable divergence. The electrode was successfully used for the potentiometric determination of duloxetine hydrochloride both in pure solutions and in pharmaceutical preparations.

Six disubstituted ligands based upon 2‐(2′‐pyridinyl/pyrazinyl)quinoline‐4‐carboxylic acids have been synthesised, solvent‐free, in one step from a range of commercially available isatin derivatives. These species behave as ancillary chelating ligands for Ir(III) complexes of the form [Ir(C^N)2(N^N)]PF6 (where C^N=cyclometalating ligand; N^N=2‐(2′‐pyridinyl/pyrazinyl)quinoline‐4‐carboxylic acids). An X‐ray crystallographic study on one complex shows a distorted octahedral geometry wherein a cis‐C,C and trans‐N,N coordination mode is observed for the cyclometalating ligands. DFT calculations predicted that variations in N^N ligand from 2,2′‐bipyridine to L1–6 should localise the LUMO on to the Ln ligand and that the complexes are predicted to display MLCT/LLCT character. All complexes displayed luminescence in the deep red part of the visible region (674–679 nm) and emit from triplet states, but with little apparent tuning as a function of L1–6. Further time‐resolved transient absorption spectroscopy supports the participation of these triplet states to the excited state character.